21 U.S.C. § 360ee–1
FDA rare neurodegenerative disease grant program
United States · Title 21 — FOOD AND DRUGS · Status: effective
Cite this
- Citation
- 21 U.S.C. § 360ee–1, FDA rare neurodegenerative disease grant program, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/454296
- Permanent ID
ys:prov:454296@1- SHA-256
d8022cab29596808013c41a40a386cf42a666b31be6c0616cec82f9a64d07a34
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall award grants and contracts to public and private entities to cover the costs of research on, and development of interventions intended to prevent, diagnose, mitigate, treat, or cure, amyotrophic lateral sclerosis and other rare neurodegenerative diseases in adults and children, including costs incurred with respect to the development and critical evaluation of tools, methods, and processes—
to increase efficiency and productivity of clinical development of therapies, including through—
Legislative history
The public laws that enacted or amended this section. Tallies are for the whole bill as it passed each chamber — often an omnibus covering far more than this provision — not a vote on this section alone.
- Accelerating Access to Critical Therapies for ALS ActHouse: 423–3Senate: no recorded tally